Recent Quotes (30 days)

You have no recent quotes
chg | %

Acasti Pharma Inc  

(Public, NASDAQ:ACST)   Watch this stock  
Find more results for acst
1.37
-0.13 (-8.66%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.35 - 1.54
52 week 1.11 - 3.36
Open 1.49
Vol / Avg. 401,919.00/1.02M
Mkt cap 22.05M
P/E     -
Div/yield     -
EPS -0.79
Shares 14.80M
Beta 1.48
Inst. own     -

Address

545 Prom du Centropolis Suite 100
LAVAL, QC H7T 0A3
Canada
+1-450-6872262 (Phone)
+1-450-6862505 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company's drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).

Officers and directors

Roderick Noel Carter Executive Chairman of the Board
Bio & Compensation  - Reuters
Janelle D'Alvise President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Linda Parinella O'Keefe Chief Financial Officer
Bio & Compensation  - Reuters
Pierre Lemieux Ph.D. Chief Operating Officer
Bio & Compensation  - Reuters
Laurent Harvey Vice President- Clinical and Non-Clinical Affairs
Bio & Compensation  - Reuters
Jean-Daniel Belanger Secretary, Director- Corporate Affairs
Bio & Compensation  - Reuters
Jean-Marie Canan Director
Age: 60
Bio & Compensation  - Reuters
Katherine Crewe Director
Bio & Compensation  - Reuters
Richard P. Schottenfeld Director
Bio & Compensation  - Reuters